Elsevier

Gynecologic Oncology

Volume 42, Issue 2, August 1991, Pages 131-136
Gynecologic Oncology

Slide presentation
Invasive vaginal carcinoma: Analysis of early-stage disease

https://doi.org/10.1016/0090-8258(91)90332-YGet rights and content

Abstract

From 1960 through 1987, 89 patients with stage I (44 patients) or II (45 patients) vaginal carcinoma (excluding melanomas) were treated primarily at the Mayo Clinic. Treatment consisted of surgery alone in 52 patients, surgery plus radiation in 14, and radiation alone in 23. The median duration of follow-up was 4.4 years. The 5-year survival (Kaplan-Meier method) was 82% for patients with stage I disease and 53% for those with stage II disease (p = 0.009). Analysis of survival according to treatment did not show statistically significant differences. This report is consistent with previous studies showing that stage is an important prognostic factor and that treatment can be individualized, including surgical treatment for primary early-stage vaginal cancer.

References (21)

There are more references available in the full text version of this article.

Cited by (74)

  • Management and outcomes of primary vaginal Cancer

    2020, Gynecologic Oncology
    Citation Excerpt :

    We observed a trend for adenocarcinomas to metastasize but with low rate of local recurrence as compared to squamous cell cancers with a higher risk for local recurrence and a lower risk for metastases. LN metastasis has been reported as a poor prognostic factor [11]. In our study, we found favorable survival in patients with solitary inguinal LN involvement as compared to pelvic LN metastasis in patients within the same stage.

  • Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer

    2020, The Lancet Oncology
    Citation Excerpt :

    These retrospective studies mainly described patients with stage I and occasionally stage II tumours.43–46 Different surgical procedures were reported in these studies, such as local excision, partial vaginectomy, radical hysterectomy, and pelvic exenteration, usually in combination with pelvic lymph node dissection and occasionally para-aortic or inguinal lymph node dissection.43–45,47 Approximately 25% of these patients who received surgery were also given adjuvant radiotherapy.43–45

  • Cancers of the Cervix, Vulva, and Vagina

    2019, Abeloff’s Clinical Oncology
  • Invasive cancer of the Vagina

    2018, Clinical Gynecologic Oncology
  • Cancers of the Cervix, Vulva, and Vagina

    2014, Abeloff's Clinical Oncology: Fifth Edition
View all citing articles on Scopus

Presented at the meeting of the Society of Gynecologic Oncologists, Orlando, FL, February 17 to 20, 1991.

View full text